Dual-targeting nanoparticle vaccine elicits a therapeutic antibody response against chronic hepatitis B
Chronic hepatitis B is caused by prolonged infection with the hepatitis B virus (HBV), which can substantially increase the risk of developing liver disease. Despite the development of preventive vaccines against HBV, a therapeutic vaccine inducing an effective antibody response still remains elusiv...
Gespeichert in:
| Veröffentlicht in: | Nature nanotechnology 2020-05, Vol.15 (5), p.406-416 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 416 |
|---|---|
| container_issue | 5 |
| container_start_page | 406 |
| container_title | Nature nanotechnology |
| container_volume | 15 |
| creator | Wang, Wenjun Zhou, Xiaoxiao Bian, Yingjie Wang, Shan Chai, Qian Guo, Zhenqian Wang, Zhenni Zhu, Ping Peng, Hua Yan, Xiyun Li, Wenhui Fu, Yang-Xin Zhu, Mingzhao |
| description | Chronic hepatitis B is caused by prolonged infection with the hepatitis B virus (HBV), which can substantially increase the risk of developing liver disease. Despite the development of preventive vaccines against HBV, a therapeutic vaccine inducing an effective antibody response still remains elusive. The preS1 domain of the large HBV surface protein is the major viral attachment site on hepatocytes and thus offers a therapeutic target; however, its poor immunogenicity limits clinical translation. Here, we design a ferritin nanoparticle vaccine that can deliver preS1 to specific myeloid cells, including SIGNR1
+
dendritic cells (which activate T follicular helper cells) and lymphatic sinus-associated SIGNR1
+
macrophages (which can activate B cells). This nanoparticle vaccine induces a high-level and persistent anti-preS1 response that results in efficient viral clearance and partial serological conversion in a chronic HBV mouse model, offering a promising translatable vaccination strategy for the functional cure of chronic hepatitis B.
A ferritin nanoparticle that delivers the preS1 domain of the large hepatitis B surface protein to two specific myeloid cell populations provides a therapeutic vaccination strategy for the treatment of chronic hepatitis B. |
| doi_str_mv | 10.1038/s41565-020-0648-y |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7223715</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2475051693</sourcerecordid><originalsourceid>FETCH-LOGICAL-c564t-dbd251f4d501b5bfc81c019f92ccfb201b2a7e9af235e13e781db36d70bfc9af3</originalsourceid><addsrcrecordid>eNp9kUtv3SAQhVHUqnm0PyCbCKlrpzyMsTeRkvQpReqmXaMxHvsSOeACjnT_fbm66U2zaFeM5nxzGDiEnHN2yZlsP6Saq0ZVTLCKNXVbbY_ICdelkLJTrw51q4_JaUr3jCnRifoNOZaCi9JnJ2T6uMJcZYgTZucn6sGHBWJ2dkb6CNY6jxRnZ11OFGjeYIQF16JT8Nn1YdjSiGkJPiGFCZxPmdpNDL4QG1wgu-wSvXlLXo8wJ3z3dJ6Rn58__bj9Wt19__Lt9vqusqqpczX0g1B8rAfFeK_60bbcMt6NnbB27EVpCtDYwSikQi5Rt3zoZTNoVtjSlmfkau-7rP0DDhZ9jjCbJboHiFsTwJmXincbM4VHo4WQmqti8P7JIIZfK6Zs7sMafdnZiForpnjTyf9TrPx7w_WO4nvKxpBSxPGwB2dml6DZJ2hKgmaXoNmWmYu_H3CY-BNZAcQeSEXyE8bnq__t-huo_6oR</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2401746173</pqid></control><display><type>article</type><title>Dual-targeting nanoparticle vaccine elicits a therapeutic antibody response against chronic hepatitis B</title><source>MEDLINE</source><source>Nature</source><source>Alma/SFX Local Collection</source><creator>Wang, Wenjun ; Zhou, Xiaoxiao ; Bian, Yingjie ; Wang, Shan ; Chai, Qian ; Guo, Zhenqian ; Wang, Zhenni ; Zhu, Ping ; Peng, Hua ; Yan, Xiyun ; Li, Wenhui ; Fu, Yang-Xin ; Zhu, Mingzhao</creator><creatorcontrib>Wang, Wenjun ; Zhou, Xiaoxiao ; Bian, Yingjie ; Wang, Shan ; Chai, Qian ; Guo, Zhenqian ; Wang, Zhenni ; Zhu, Ping ; Peng, Hua ; Yan, Xiyun ; Li, Wenhui ; Fu, Yang-Xin ; Zhu, Mingzhao</creatorcontrib><description>Chronic hepatitis B is caused by prolonged infection with the hepatitis B virus (HBV), which can substantially increase the risk of developing liver disease. Despite the development of preventive vaccines against HBV, a therapeutic vaccine inducing an effective antibody response still remains elusive. The preS1 domain of the large HBV surface protein is the major viral attachment site on hepatocytes and thus offers a therapeutic target; however, its poor immunogenicity limits clinical translation. Here, we design a ferritin nanoparticle vaccine that can deliver preS1 to specific myeloid cells, including SIGNR1
+
dendritic cells (which activate T follicular helper cells) and lymphatic sinus-associated SIGNR1
+
macrophages (which can activate B cells). This nanoparticle vaccine induces a high-level and persistent anti-preS1 response that results in efficient viral clearance and partial serological conversion in a chronic HBV mouse model, offering a promising translatable vaccination strategy for the functional cure of chronic hepatitis B.
A ferritin nanoparticle that delivers the preS1 domain of the large hepatitis B surface protein to two specific myeloid cell populations provides a therapeutic vaccination strategy for the treatment of chronic hepatitis B.</description><identifier>ISSN: 1748-3387</identifier><identifier>EISSN: 1748-3395</identifier><identifier>DOI: 10.1038/s41565-020-0648-y</identifier><identifier>PMID: 32123380</identifier><language>eng</language><publisher>London: Nature Publishing Group UK</publisher><subject>631/61 ; 631/61/350 ; 631/61/350/354 ; Animals ; Antibodies ; Antibody Formation ; Antibody response ; Chemistry and Materials Science ; Chronic infection ; Dendritic cells ; Domains ; Drug delivery systems ; Female ; Ferritin ; Helper cells ; Hepatitis ; Hepatitis B ; Hepatitis B Surface Antigens - administration & dosage ; Hepatitis B Surface Antigens - therapeutic use ; Hepatitis B Vaccines - administration & dosage ; Hepatitis B Vaccines - therapeutic use ; Hepatitis B virus - immunology ; Hepatitis B, Chronic - immunology ; Hepatitis B, Chronic - prevention & control ; Hepatocytes ; Immunization ; Immunogenicity ; Interferon ; Liver diseases ; Lymphocytes B ; Macrophages ; Male ; Materials Science ; Mice, Inbred BALB C ; Mice, Inbred C57BL ; Myeloid cells ; Myeloid Cells - immunology ; Nanoparticles ; Nanoparticles - administration & dosage ; Nanoparticles - therapeutic use ; Nanotechnology ; Nanotechnology and Microengineering ; Protein Precursors - administration & dosage ; Protein Precursors - therapeutic use ; Proteins ; Therapeutic applications ; Vaccines ; Virus attachment ; Viruses</subject><ispartof>Nature nanotechnology, 2020-05, Vol.15 (5), p.406-416</ispartof><rights>The Author(s), under exclusive licence to Springer Nature Limited 2020</rights><rights>The Author(s), under exclusive licence to Springer Nature Limited 2020.</rights><rights>Copyright Nature Publishing Group May 2020</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c564t-dbd251f4d501b5bfc81c019f92ccfb201b2a7e9af235e13e781db36d70bfc9af3</citedby><cites>FETCH-LOGICAL-c564t-dbd251f4d501b5bfc81c019f92ccfb201b2a7e9af235e13e781db36d70bfc9af3</cites><orcidid>0000-0002-9599-9907 ; 0000-0003-2648-3170 ; 0000-0002-2482-5475 ; 0000-0002-4809-825X ; 0000-0003-2001-2669</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,780,784,885,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32123380$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Wang, Wenjun</creatorcontrib><creatorcontrib>Zhou, Xiaoxiao</creatorcontrib><creatorcontrib>Bian, Yingjie</creatorcontrib><creatorcontrib>Wang, Shan</creatorcontrib><creatorcontrib>Chai, Qian</creatorcontrib><creatorcontrib>Guo, Zhenqian</creatorcontrib><creatorcontrib>Wang, Zhenni</creatorcontrib><creatorcontrib>Zhu, Ping</creatorcontrib><creatorcontrib>Peng, Hua</creatorcontrib><creatorcontrib>Yan, Xiyun</creatorcontrib><creatorcontrib>Li, Wenhui</creatorcontrib><creatorcontrib>Fu, Yang-Xin</creatorcontrib><creatorcontrib>Zhu, Mingzhao</creatorcontrib><title>Dual-targeting nanoparticle vaccine elicits a therapeutic antibody response against chronic hepatitis B</title><title>Nature nanotechnology</title><addtitle>Nat. Nanotechnol</addtitle><addtitle>Nat Nanotechnol</addtitle><description>Chronic hepatitis B is caused by prolonged infection with the hepatitis B virus (HBV), which can substantially increase the risk of developing liver disease. Despite the development of preventive vaccines against HBV, a therapeutic vaccine inducing an effective antibody response still remains elusive. The preS1 domain of the large HBV surface protein is the major viral attachment site on hepatocytes and thus offers a therapeutic target; however, its poor immunogenicity limits clinical translation. Here, we design a ferritin nanoparticle vaccine that can deliver preS1 to specific myeloid cells, including SIGNR1
+
dendritic cells (which activate T follicular helper cells) and lymphatic sinus-associated SIGNR1
+
macrophages (which can activate B cells). This nanoparticle vaccine induces a high-level and persistent anti-preS1 response that results in efficient viral clearance and partial serological conversion in a chronic HBV mouse model, offering a promising translatable vaccination strategy for the functional cure of chronic hepatitis B.
A ferritin nanoparticle that delivers the preS1 domain of the large hepatitis B surface protein to two specific myeloid cell populations provides a therapeutic vaccination strategy for the treatment of chronic hepatitis B.</description><subject>631/61</subject><subject>631/61/350</subject><subject>631/61/350/354</subject><subject>Animals</subject><subject>Antibodies</subject><subject>Antibody Formation</subject><subject>Antibody response</subject><subject>Chemistry and Materials Science</subject><subject>Chronic infection</subject><subject>Dendritic cells</subject><subject>Domains</subject><subject>Drug delivery systems</subject><subject>Female</subject><subject>Ferritin</subject><subject>Helper cells</subject><subject>Hepatitis</subject><subject>Hepatitis B</subject><subject>Hepatitis B Surface Antigens - administration & dosage</subject><subject>Hepatitis B Surface Antigens - therapeutic use</subject><subject>Hepatitis B Vaccines - administration & dosage</subject><subject>Hepatitis B Vaccines - therapeutic use</subject><subject>Hepatitis B virus - immunology</subject><subject>Hepatitis B, Chronic - immunology</subject><subject>Hepatitis B, Chronic - prevention & control</subject><subject>Hepatocytes</subject><subject>Immunization</subject><subject>Immunogenicity</subject><subject>Interferon</subject><subject>Liver diseases</subject><subject>Lymphocytes B</subject><subject>Macrophages</subject><subject>Male</subject><subject>Materials Science</subject><subject>Mice, Inbred BALB C</subject><subject>Mice, Inbred C57BL</subject><subject>Myeloid cells</subject><subject>Myeloid Cells - immunology</subject><subject>Nanoparticles</subject><subject>Nanoparticles - administration & dosage</subject><subject>Nanoparticles - therapeutic use</subject><subject>Nanotechnology</subject><subject>Nanotechnology and Microengineering</subject><subject>Protein Precursors - administration & dosage</subject><subject>Protein Precursors - therapeutic use</subject><subject>Proteins</subject><subject>Therapeutic applications</subject><subject>Vaccines</subject><subject>Virus attachment</subject><subject>Viruses</subject><issn>1748-3387</issn><issn>1748-3395</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNp9kUtv3SAQhVHUqnm0PyCbCKlrpzyMsTeRkvQpReqmXaMxHvsSOeACjnT_fbm66U2zaFeM5nxzGDiEnHN2yZlsP6Saq0ZVTLCKNXVbbY_ICdelkLJTrw51q4_JaUr3jCnRifoNOZaCi9JnJ2T6uMJcZYgTZucn6sGHBWJ2dkb6CNY6jxRnZ11OFGjeYIQF16JT8Nn1YdjSiGkJPiGFCZxPmdpNDL4QG1wgu-wSvXlLXo8wJ3z3dJ6Rn58__bj9Wt19__Lt9vqusqqpczX0g1B8rAfFeK_60bbcMt6NnbB27EVpCtDYwSikQi5Rt3zoZTNoVtjSlmfkau-7rP0DDhZ9jjCbJboHiFsTwJmXincbM4VHo4WQmqti8P7JIIZfK6Zs7sMafdnZiForpnjTyf9TrPx7w_WO4nvKxpBSxPGwB2dml6DZJ2hKgmaXoNmWmYu_H3CY-BNZAcQeSEXyE8bnq__t-huo_6oR</recordid><startdate>20200501</startdate><enddate>20200501</enddate><creator>Wang, Wenjun</creator><creator>Zhou, Xiaoxiao</creator><creator>Bian, Yingjie</creator><creator>Wang, Shan</creator><creator>Chai, Qian</creator><creator>Guo, Zhenqian</creator><creator>Wang, Zhenni</creator><creator>Zhu, Ping</creator><creator>Peng, Hua</creator><creator>Yan, Xiyun</creator><creator>Li, Wenhui</creator><creator>Fu, Yang-Xin</creator><creator>Zhu, Mingzhao</creator><general>Nature Publishing Group UK</general><general>Nature Publishing Group</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QO</scope><scope>7U5</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FD</scope><scope>8FE</scope><scope>8FG</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABJCF</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>ARAPS</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BGLVJ</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>D1I</scope><scope>DWQXO</scope><scope>F28</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB.</scope><scope>L6V</scope><scope>L7M</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7P</scope><scope>M7S</scope><scope>P5Z</scope><scope>P62</scope><scope>P64</scope><scope>PDBOC</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PTHSS</scope><scope>PRINS</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-9599-9907</orcidid><orcidid>https://orcid.org/0000-0003-2648-3170</orcidid><orcidid>https://orcid.org/0000-0002-2482-5475</orcidid><orcidid>https://orcid.org/0000-0002-4809-825X</orcidid><orcidid>https://orcid.org/0000-0003-2001-2669</orcidid></search><sort><creationdate>20200501</creationdate><title>Dual-targeting nanoparticle vaccine elicits a therapeutic antibody response against chronic hepatitis B</title><author>Wang, Wenjun ; Zhou, Xiaoxiao ; Bian, Yingjie ; Wang, Shan ; Chai, Qian ; Guo, Zhenqian ; Wang, Zhenni ; Zhu, Ping ; Peng, Hua ; Yan, Xiyun ; Li, Wenhui ; Fu, Yang-Xin ; Zhu, Mingzhao</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c564t-dbd251f4d501b5bfc81c019f92ccfb201b2a7e9af235e13e781db36d70bfc9af3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>631/61</topic><topic>631/61/350</topic><topic>631/61/350/354</topic><topic>Animals</topic><topic>Antibodies</topic><topic>Antibody Formation</topic><topic>Antibody response</topic><topic>Chemistry and Materials Science</topic><topic>Chronic infection</topic><topic>Dendritic cells</topic><topic>Domains</topic><topic>Drug delivery systems</topic><topic>Female</topic><topic>Ferritin</topic><topic>Helper cells</topic><topic>Hepatitis</topic><topic>Hepatitis B</topic><topic>Hepatitis B Surface Antigens - administration & dosage</topic><topic>Hepatitis B Surface Antigens - therapeutic use</topic><topic>Hepatitis B Vaccines - administration & dosage</topic><topic>Hepatitis B Vaccines - therapeutic use</topic><topic>Hepatitis B virus - immunology</topic><topic>Hepatitis B, Chronic - immunology</topic><topic>Hepatitis B, Chronic - prevention & control</topic><topic>Hepatocytes</topic><topic>Immunization</topic><topic>Immunogenicity</topic><topic>Interferon</topic><topic>Liver diseases</topic><topic>Lymphocytes B</topic><topic>Macrophages</topic><topic>Male</topic><topic>Materials Science</topic><topic>Mice, Inbred BALB C</topic><topic>Mice, Inbred C57BL</topic><topic>Myeloid cells</topic><topic>Myeloid Cells - immunology</topic><topic>Nanoparticles</topic><topic>Nanoparticles - administration & dosage</topic><topic>Nanoparticles - therapeutic use</topic><topic>Nanotechnology</topic><topic>Nanotechnology and Microengineering</topic><topic>Protein Precursors - administration & dosage</topic><topic>Protein Precursors - therapeutic use</topic><topic>Proteins</topic><topic>Therapeutic applications</topic><topic>Vaccines</topic><topic>Virus attachment</topic><topic>Viruses</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Wang, Wenjun</creatorcontrib><creatorcontrib>Zhou, Xiaoxiao</creatorcontrib><creatorcontrib>Bian, Yingjie</creatorcontrib><creatorcontrib>Wang, Shan</creatorcontrib><creatorcontrib>Chai, Qian</creatorcontrib><creatorcontrib>Guo, Zhenqian</creatorcontrib><creatorcontrib>Wang, Zhenni</creatorcontrib><creatorcontrib>Zhu, Ping</creatorcontrib><creatorcontrib>Peng, Hua</creatorcontrib><creatorcontrib>Yan, Xiyun</creatorcontrib><creatorcontrib>Li, Wenhui</creatorcontrib><creatorcontrib>Fu, Yang-Xin</creatorcontrib><creatorcontrib>Zhu, Mingzhao</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Biotechnology Research Abstracts</collection><collection>Solid State and Superconductivity Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Technology Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Materials Science & Engineering Collection</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>Advanced Technologies & Aerospace Collection</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Technology Collection</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Materials Science Collection</collection><collection>ProQuest Central Korea</collection><collection>ANTE: Abstracts in New Technology & Engineering</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Materials Science Database</collection><collection>ProQuest Engineering Collection</collection><collection>Advanced Technologies Database with Aerospace</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Biological Science Database</collection><collection>Engineering Database</collection><collection>Advanced Technologies & Aerospace Database</collection><collection>ProQuest Advanced Technologies & Aerospace Collection</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Materials Science Collection</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>Engineering Collection</collection><collection>ProQuest Central China</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Nature nanotechnology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Wang, Wenjun</au><au>Zhou, Xiaoxiao</au><au>Bian, Yingjie</au><au>Wang, Shan</au><au>Chai, Qian</au><au>Guo, Zhenqian</au><au>Wang, Zhenni</au><au>Zhu, Ping</au><au>Peng, Hua</au><au>Yan, Xiyun</au><au>Li, Wenhui</au><au>Fu, Yang-Xin</au><au>Zhu, Mingzhao</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Dual-targeting nanoparticle vaccine elicits a therapeutic antibody response against chronic hepatitis B</atitle><jtitle>Nature nanotechnology</jtitle><stitle>Nat. Nanotechnol</stitle><addtitle>Nat Nanotechnol</addtitle><date>2020-05-01</date><risdate>2020</risdate><volume>15</volume><issue>5</issue><spage>406</spage><epage>416</epage><pages>406-416</pages><issn>1748-3387</issn><eissn>1748-3395</eissn><abstract>Chronic hepatitis B is caused by prolonged infection with the hepatitis B virus (HBV), which can substantially increase the risk of developing liver disease. Despite the development of preventive vaccines against HBV, a therapeutic vaccine inducing an effective antibody response still remains elusive. The preS1 domain of the large HBV surface protein is the major viral attachment site on hepatocytes and thus offers a therapeutic target; however, its poor immunogenicity limits clinical translation. Here, we design a ferritin nanoparticle vaccine that can deliver preS1 to specific myeloid cells, including SIGNR1
+
dendritic cells (which activate T follicular helper cells) and lymphatic sinus-associated SIGNR1
+
macrophages (which can activate B cells). This nanoparticle vaccine induces a high-level and persistent anti-preS1 response that results in efficient viral clearance and partial serological conversion in a chronic HBV mouse model, offering a promising translatable vaccination strategy for the functional cure of chronic hepatitis B.
A ferritin nanoparticle that delivers the preS1 domain of the large hepatitis B surface protein to two specific myeloid cell populations provides a therapeutic vaccination strategy for the treatment of chronic hepatitis B.</abstract><cop>London</cop><pub>Nature Publishing Group UK</pub><pmid>32123380</pmid><doi>10.1038/s41565-020-0648-y</doi><tpages>11</tpages><orcidid>https://orcid.org/0000-0002-9599-9907</orcidid><orcidid>https://orcid.org/0000-0003-2648-3170</orcidid><orcidid>https://orcid.org/0000-0002-2482-5475</orcidid><orcidid>https://orcid.org/0000-0002-4809-825X</orcidid><orcidid>https://orcid.org/0000-0003-2001-2669</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1748-3387 |
| ispartof | Nature nanotechnology, 2020-05, Vol.15 (5), p.406-416 |
| issn | 1748-3387 1748-3395 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7223715 |
| source | MEDLINE; Nature; Alma/SFX Local Collection |
| subjects | 631/61 631/61/350 631/61/350/354 Animals Antibodies Antibody Formation Antibody response Chemistry and Materials Science Chronic infection Dendritic cells Domains Drug delivery systems Female Ferritin Helper cells Hepatitis Hepatitis B Hepatitis B Surface Antigens - administration & dosage Hepatitis B Surface Antigens - therapeutic use Hepatitis B Vaccines - administration & dosage Hepatitis B Vaccines - therapeutic use Hepatitis B virus - immunology Hepatitis B, Chronic - immunology Hepatitis B, Chronic - prevention & control Hepatocytes Immunization Immunogenicity Interferon Liver diseases Lymphocytes B Macrophages Male Materials Science Mice, Inbred BALB C Mice, Inbred C57BL Myeloid cells Myeloid Cells - immunology Nanoparticles Nanoparticles - administration & dosage Nanoparticles - therapeutic use Nanotechnology Nanotechnology and Microengineering Protein Precursors - administration & dosage Protein Precursors - therapeutic use Proteins Therapeutic applications Vaccines Virus attachment Viruses |
| title | Dual-targeting nanoparticle vaccine elicits a therapeutic antibody response against chronic hepatitis B |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T14%3A12%3A42IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Dual-targeting%20nanoparticle%20vaccine%20elicits%20a%20therapeutic%20antibody%20response%20against%20chronic%20hepatitis%20B&rft.jtitle=Nature%20nanotechnology&rft.au=Wang,%20Wenjun&rft.date=2020-05-01&rft.volume=15&rft.issue=5&rft.spage=406&rft.epage=416&rft.pages=406-416&rft.issn=1748-3387&rft.eissn=1748-3395&rft_id=info:doi/10.1038/s41565-020-0648-y&rft_dat=%3Cproquest_pubme%3E2475051693%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2401746173&rft_id=info:pmid/32123380&rfr_iscdi=true |